ALX Oncology Holdings Inc. (ALXO) stock rallied over 2.84% intraday to trade at $9.41 a share on NASDAQ. The stock opened with a gain of 16.60% at $9.13 and touched an intraday high of $9.47, rising 2.84% against the last close of $9.15. The stock went to a low of $9.021 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALX Oncology Holdings Inc. (NASDAQ: ALXO) stock price is $9.41 as of the last check on Wednesday, July 6. During the trading session, ALXO stock reached the peak price of $9.47 while $9.021 was the lowest point it dropped to.
The NASDAQ listed ALXO is part of Biotechnology industry that operates in the broader Health Care sector. ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer.
Dr. Jaume Pons Ph.D.
Pres, CEO & Director
Dr. Michael Warner J.D., Ph.D.
Dr. Corey S. Goodman Ph.D.
Independent Exec. Chairman
Dr. Jaume Pons Ph.D.
Founder, Pres, CEO & Director
ALXO stock traded closed the last session at $9.41, which is $0.26 or 2.84% lower than its previous close of $9.15. ALXO's current trading price is 61.68% lower than its 52-week high of $81.19 where as its distance from 52-week low of 5.82% is -88.41%.
Number of ALXO employees currently stands at -. ALXO operates from 323 Allerton Avenue, South San Francisco, CA 94080, United States.
Official Webiste of $ALXO is: https://www.alxoncology.com
ALXO stock volume for the day was 252,759 shares while in the previous session number of ALXO shares traded was 256,329 . The average number of ALXO shares traded daily for last 3 months was 480.63 Thousands.
The percentage change in ALXO stock occurred in the recent session was 2.84% while the dollar amount for the price change in ALXO stock was $0.26.
In the recent session, the day high for ALXO stock was $9.47 while the low for ALXO stock touched on the day was $9.021.
The market value of ALXO currently stands at 376.31 Million with its latest stock price at $9.41 and 40.62 Million of its shares outstanding.